Table 2.
Patients’ characteristics according to dichotomized distribution of OX40 positive immune cells in primary cancer biopsies in the overall cohort (cut-off = 36.5 cells; n = 47)a
| OX40 high | OX40 low | p-value | |
|---|---|---|---|
| n = 14 (100%) | n = 33 (100%) | ||
| Age (median, range) | 57 (41–73) | 59 (34–77) | 0.464 |
| FIGO stage | 0.795 | ||
| II | 0 | 1 (3.0) | |
| IIIA | 0 | 1 (3.0) | |
| IIIB | 2 (14.3) | 3 (9.1) | |
| IIIC | 11 (78.6) | 21 (63.6) | |
| IV | 1 (14.1) | 7 (21.2) | |
| Residual disease | 0.243 | ||
| None | 7 (50.0) | 9 (27.3) | |
| < 2 cm | 5 (35.7) | 12 (36.4) | |
| > 2 cm | 2 (14.3) | 11 (33.3) | |
| Numbers of chemotherapy cycles | 0.057 | ||
| < 6 | 0 | 7 (21.2) | |
| 6 or more | 14 (100.0) | 25 (75.8) | |
| CSb | 13 (93.0) | 20 (60.6) | 0.027 |
| CRb | 1 (14.1) | 13 (39.4) | |
| 6-month RFS % (95%CI)c | 0.71 (0.41–0.88) | 0.45 (0.28–0.61) | 0.461 |
| 3-year OS % (95%CI)c | 0.38 (0.10–0.67) | 0.46 (0.26–0.64) | 0.780 |
apercentages may not add to 100% due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kaplan-Meier method. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Chi-Square or the Fisher’s Exact test
bCS chemosensitive, CR chemoresistant
cRFS recurrence-free survival, OS overall survival